8.48 USD
-0.13 (-1.51%)
At close: Feb 11, 2026
8.48 USD
0 (0%)
After Hours: 2/11/2026, 8:00:46 PM
ZVRA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of ZVRA have multiple concerns. ZVRA is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
- ZVRA had positive earnings in the past year.
- ZVRA had a negative operating cash flow in the past year.
- In the past 5 years ZVRA always reported negative net income.
- In the past 5 years ZVRA reported 4 times negative operating cash flow.
1.2 Ratios
- ZVRA has a better Return On Assets (13.08%) than 94.24% of its industry peers.
- With an excellent Return On Equity value of 26.53%, ZVRA belongs to the best of the industry, outperforming 92.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.08% | ||
| ROE | 26.53% | ||
| ROIC | N/A |
ROA(3y)-40.64%
ROA(5y)-56.64%
ROE(3y)-129.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Profit Margin, with a value of 41.86%, ZVRA belongs to the top of the industry, outperforming 97.38% of the companies in the same industry.
- ZVRA has a Gross Margin of 93.88%. This is amongst the best in the industry. ZVRA outperforms 95.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 41.86% | ||
| GM | 93.88% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- ZVRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
- ZVRA has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for ZVRA has been increased compared to 5 years ago.
- The debt/assets ratio for ZVRA is higher compared to a year ago.
2.2 Solvency
- ZVRA has an Altman-Z score of 0.68. This is a bad value and indicates that ZVRA is not financially healthy and even has some risk of bankruptcy.
- ZVRA has a Altman-Z score of 0.68. This is comparable to the rest of the industry: ZVRA outperforms 51.31% of its industry peers.
- A Debt/Equity ratio of 0.46 indicates that ZVRA is not too dependend on debt financing.
- With a Debt to Equity ratio value of 0.46, ZVRA is not doing good in the industry: 61.26% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.68 |
ROIC/WACCN/A
WACC9.68%
2.3 Liquidity
- A Current Ratio of 8.62 indicates that ZVRA has no problem at all paying its short term obligations.
- ZVRA's Current ratio of 8.62 is fine compared to the rest of the industry. ZVRA outperforms 75.39% of its industry peers.
- A Quick Ratio of 8.57 indicates that ZVRA has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 8.57, ZVRA is in the better half of the industry, outperforming 75.92% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.62 | ||
| Quick Ratio | 8.57 |
3. Growth
3.1 Past
- ZVRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 122.84%, which is quite impressive.
- Looking at the last year, ZVRA shows a very strong growth in Revenue. The Revenue has grown by 240.47%.
- Measured over the past years, ZVRA shows a quite strong growth in Revenue. The Revenue has been growing by 12.96% on average per year.
EPS 1Y (TTM)122.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.55%
Revenue 1Y (TTM)240.47%
Revenue growth 3Y-6.24%
Revenue growth 5Y12.96%
Sales Q2Q%605.36%
3.2 Future
- The Earnings Per Share is expected to grow by 28.20% on average over the next years. This is a very strong growth
- Based on estimates for the next years, ZVRA will show a very strong growth in Revenue. The Revenue will grow by 76.65% on average per year.
EPS Next Y155.85%
EPS Next 2Y50.02%
EPS Next 3Y39.67%
EPS Next 5Y28.2%
Revenue Next Year389.32%
Revenue Next 2Y165.63%
Revenue Next 3Y121.31%
Revenue Next 5Y76.65%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 18.84, the valuation of ZVRA can be described as rather expensive.
- ZVRA's Price/Earnings ratio is rather cheap when compared to the industry. ZVRA is cheaper than 83.25% of the companies in the same industry.
- The average S&P500 Price/Earnings ratio is at 28.18. ZVRA is valued slightly cheaper when compared to this.
- With a Price/Forward Earnings ratio of 14.98, ZVRA is valued correctly.
- Based on the Price/Forward Earnings ratio, ZVRA is valued cheaper than 82.72% of the companies in the same industry.
- ZVRA's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 28.01.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.84 | ||
| Fwd PE | 14.98 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- ZVRA's earnings are expected to grow with 39.67% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.12
PEG (5Y)N/A
EPS Next 2Y50.02%
EPS Next 3Y39.67%
5. Dividend
5.1 Amount
- ZVRA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
8.48
-0.13 (-1.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)03-09 2026-03-09/amc
Inst Owners70.03%
Inst Owner ChangeN/A
Ins Owners0.69%
Ins Owner Change32.95%
Market Cap477.42M
Revenue(TTM)84.39M
Net Income(TTM)35.33M
Analysts84.29
Price Target23.31 (174.88%)
Short Float %7.27%
Short Ratio3.79
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)25.59%
Min EPS beat(2)-20.8%
Max EPS beat(2)71.99%
EPS beat(4)2
Avg EPS beat(4)13.08%
Min EPS beat(4)-67.34%
Max EPS beat(4)71.99%
EPS beat(8)3
Avg EPS beat(8)-5.61%
EPS beat(12)4
Avg EPS beat(12)-9.16%
EPS beat(16)5
Avg EPS beat(16)-12.64%
Revenue beat(2)1
Avg Revenue beat(2)4.28%
Min Revenue beat(2)-4.04%
Max Revenue beat(2)12.59%
Revenue beat(4)3
Avg Revenue beat(4)14.7%
Min Revenue beat(4)-4.04%
Max Revenue beat(4)32.28%
Revenue beat(8)5
Avg Revenue beat(8)4.12%
Revenue beat(12)7
Avg Revenue beat(12)14.01%
Revenue beat(16)9
Avg Revenue beat(16)10.43%
PT rev (1m)0%
PT rev (3m)-4.76%
EPS NQ rev (1m)17.65%
EPS NQ rev (3m)310.53%
EPS NY rev (1m)-3.32%
EPS NY rev (3m)2.91%
Revenue NQ rev (1m)-0.05%
Revenue NQ rev (3m)-0.16%
Revenue NY rev (1m)0.09%
Revenue NY rev (3m)-0.64%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.84 | ||
| Fwd PE | 14.98 | ||
| P/S | 5.66 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.59 | ||
| P/tB | 3.92 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.45
EY5.31%
EPS(NY)0.57
Fwd EY6.68%
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS1.5
BVpS2.37
TBVpS2.16
PEG (NY)0.12
PEG (5Y)N/A
Graham Number4.89
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.08% | ||
| ROE | 26.53% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 41.86% | ||
| GM | 93.88% | ||
| FCFM | N/A |
ROA(3y)-40.64%
ROA(5y)-56.64%
ROE(3y)-129.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.31
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 128.58% | ||
| Cap/Sales | 8.14% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.62 | ||
| Quick Ratio | 8.57 | ||
| Altman-Z | 0.68 |
F-Score6
WACC9.68%
ROIC/WACCN/A
Cap/Depr(3y)44.3%
Cap/Depr(5y)36.5%
Cap/Sales(3y)9.12%
Cap/Sales(5y)5.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)122.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.55%
EPS Next Y155.85%
EPS Next 2Y50.02%
EPS Next 3Y39.67%
EPS Next 5Y28.2%
Revenue 1Y (TTM)240.47%
Revenue growth 3Y-6.24%
Revenue growth 5Y12.96%
Sales Q2Q%605.36%
Revenue Next Year389.32%
Revenue Next 2Y165.63%
Revenue Next 3Y121.31%
Revenue Next 5Y76.65%
EBIT growth 1Y66.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year29.54%
EBIT Next 3Y40.04%
EBIT Next 5Y32.31%
FCF growth 1Y-36.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.98%
OCF growth 3YN/A
OCF growth 5YN/A
ZEVRA THERAPEUTICS INC / ZVRA FAQ
What is the fundamental rating for ZVRA stock?
ChartMill assigns a fundamental rating of 4 / 10 to ZVRA.
What is the valuation status for ZVRA stock?
ChartMill assigns a valuation rating of 5 / 10 to ZEVRA THERAPEUTICS INC (ZVRA). This can be considered as Fairly Valued.
What is the profitability of ZVRA stock?
ZEVRA THERAPEUTICS INC (ZVRA) has a profitability rating of 3 / 10.
What is the earnings growth outlook for ZEVRA THERAPEUTICS INC?
The Earnings per Share (EPS) of ZEVRA THERAPEUTICS INC (ZVRA) is expected to grow by 155.85% in the next year.